-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AOC-1044 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1044 in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1044 in Duchenne Muscular Dystrophy Drug Details: AOC-1044 is under...
-
Product Insights
NewNet Present Value Model: Avidity Biosciences Inc’s AOC-1020
Empower your strategies with our Net Present Value Model: Avidity Biosciences Inc's AOC-1020 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AOC-1001 in Myotonic Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1001 in Myotonic Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1001 in Myotonic Dystrophy Drug Details: AOC-1001 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AOC-1020 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1020 in Facioscapulohumeral Muscular Dystrophy (FSHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1020 in Facioscapulohumeral Muscular Dystrophy (FSHD) Drug Details: AOC-1020 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZEN-3694 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZEN-3694 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZEN-3694 in Solid Tumor Drug Details: ZEN-3694 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanzalintinib Fumarate in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanzalintinib Fumarate in Hypopharyngeal Cancer Drug Details: Zanzalintinib fumarate (XL-092) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erdafitinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erdafitinib in Solid Tumor Drug Details: Erdafitinib (Balversa, Erfandel) is an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Danvilostomig in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danvilostomig in Hypopharyngeal Cancer Drug Details: Danvilostomig (SIB-003) is under development for...
-
Product Insights
NewNet Present Value Model: Ultragenyx Pharmaceutical Inc’s Setrusumab
Empower your strategies with our Net Present Value Model: Ultragenyx Pharmaceutical Inc's Setrusumab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-3907 in Liver Diseases
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. A-3907 in Liver Diseases Drug Details: A-3907 is under development for the treatment of adult...